DHIVY
Peakcarbidopa levodopa
NDAORALTABLET
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
DHIVY (carbidopa levodopa) is dopa decarboxylase inhibitors [moa]. First approved in 2021.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DHIVY is an oral tablet combining carbidopa and levodopa, approved in November 2021 for Parkinson Disease treatment. It works as a DOPA decarboxylase inhibitor to increase dopamine availability in the brain. This is a well-established mechanism for managing motor symptoms in Parkinson patients.
$0.995MPart D
Peak12.9 years to LOEDHIVY is in peak commercial phase with modest Part D utilization ($995K in 2023), suggesting a niche market position within a crowded Parkinson franchise.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DHIVY currently shows no linked job openings in available career databases, suggesting a small dedicated brand team or minimal active hiring. This indicates either a mature, stable team structure or a lower commercial priority within the Parkinson portfolio.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.